We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Daiichi Sankyo Company, Limited has launched the antitumor agent trastuzumab Biosimilar for intravenous drip infusions 60 mg and 150 mg “Daiichi Sankyo” in Japan.